Prediction of Acute Kidney Injury by Fibroblast Growth Factor 23 (FGF-23) in Adult Patients, A Meta-analysis Study.

IF 0.8 4区医学 Q4 UROLOGY & NEPHROLOGY

Iranian journal of kidney diseases Pub Date : 2023-01-01

Wei Tao, Shu-Wen Guo, Yu-Jie Fan, Feng Zheng

{"title":"Prediction of Acute Kidney Injury by Fibroblast Growth Factor 23 (FGF-23) in Adult Patients, A Meta-analysis Study.","authors":"Wei Tao, Shu-Wen Guo, Yu-Jie Fan, Feng Zheng","doi":"","DOIUrl":null,"url":null,"abstract":"Introduction: The aim of the current meta-analysis was to assess the predictive value of blood fibroblast growth factor 23 (FGF-23) for acute kidney injury (AKI) in adult patients.Methods: We retrieved relative publications from electronic databases including the Cochrane Library, PubMed, Google Scholar, Scopus, web of science, and Wanfang Data from their inception to Aug 2022.Results: This meta-analysis study included seven prospective cohort trials comprising 1,655 adult patients. The overall pooled area under the receiver operating characteristic curve (AUC) from seven studies was 0.83 (95% CI: 0.80 to 0.86). Significant heterogeneity was identified (Q = 9.82, P = .004, I2 = 80). Pooled sensitivity and specificity were 0.75 (95% CI: 0.59 to 0.87) and 0.77 (95% CI: 0.65 to 0.87), respectively. Pooled positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 3.3 (95% CI: 1.8 to 6.3), 0.32 (95% CI: 0.16 to 0.63), and 10 (95% CI: 3 to 38); respectively. Moreover, our sensitivity analysis showed that when a trial from Asia was excluded, the predictive value of FGF-23 was declined.Conclusion: Our results of meta-analysis of seven prospective cohort trials suggested that blood FGF-23 is a candidate indicator for the prediction of AKI in adult patients. Results of future large and well-designed clinical trials are still needed. DOI: 10.52547/ijkd.7189.","PeriodicalId":14610,"journal":{"name":"Iranian journal of kidney diseases","volume":"1 1","pages":"1-8"},"PeriodicalIF":0.8000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian journal of kidney diseases","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The aim of the current meta-analysis was to assess the predictive value of blood fibroblast growth factor 23 (FGF-23) for acute kidney injury (AKI) in adult patients.

Methods: We retrieved relative publications from electronic databases including the Cochrane Library, PubMed, Google Scholar, Scopus, web of science, and Wanfang Data from their inception to Aug 2022.

Results: This meta-analysis study included seven prospective cohort trials comprising 1,655 adult patients. The overall pooled area under the receiver operating characteristic curve (AUC) from seven studies was 0.83 (95% CI: 0.80 to 0.86). Significant heterogeneity was identified (Q = 9.82, P = .004, I2 = 80). Pooled sensitivity and specificity were 0.75 (95% CI: 0.59 to 0.87) and 0.77 (95% CI: 0.65 to 0.87), respectively. Pooled positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were 3.3 (95% CI: 1.8 to 6.3), 0.32 (95% CI: 0.16 to 0.63), and 10 (95% CI: 3 to 38); respectively. Moreover, our sensitivity analysis showed that when a trial from Asia was excluded, the predictive value of FGF-23 was declined.

Conclusion: Our results of meta-analysis of seven prospective cohort trials suggested that blood FGF-23 is a candidate indicator for the prediction of AKI in adult patients. Results of future large and well-designed clinical trials are still needed. DOI: 10.52547/ijkd.7189.

本刊更多论文

成纤维细胞生长因子23 (FGF-23)预测成人患者急性肾损伤的meta分析研究

当前荟萃分析的目的是评估血成纤维细胞生长因子23 (FGF-23)对成年患者急性肾损伤(AKI)的预测价值。方法:我们从Cochrane Library、PubMed、Google Scholar、Scopus、web of science和Wanfang Data等电子数据库中检索自成立至2022年8月的相关出版物。结果:这项荟萃分析研究包括7项前瞻性队列试验，包括1,655名成年患者。7项研究的受试者工作特征曲线(AUC)下的总汇总面积为0.83 (95% CI: 0.80 ~ 0.86)。存在显著异质性(Q = 9.82, P = 0.004, I2 = 80)。合并敏感性和特异性分别为0.75 (95% CI: 0.59 ~ 0.87)和0.77 (95% CI: 0.65 ~ 0.87)。合并阳性似然比、阴性似然比和诊断优势比分别为3.3 (95% CI: 1.8 ~ 6.3)、0.32 (95% CI: 0.16 ~ 0.63)和10 (95% CI: 3 ~ 38);分别。此外，我们的敏感性分析显示，当排除来自亚洲的试验时，FGF-23的预测价值下降。结论:我们对7项前瞻性队列试验的荟萃分析结果表明，血液FGF-23是预测成人患者AKI的候选指标。未来大型和精心设计的临床试验的结果仍然需要。DOI: 10.52547 / ijkd.7189。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Iranian journal of kidney diseases UROLOGY & NEPHROLOGY-

CiteScore

2.50

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Iranian Journal of Kidney Diseases (IJKD), a peer-reviewed journal in English, is the official publication of the Iranian Society of Nephrology. The aim of the IJKD is the worldwide reflection of the knowledge produced by the scientists and clinicians in nephrology. Published quarterly, the IJKD provides a new platform for advancement of the field. The journal’s objective is to serve as a focal point for debates and exchange of knowledge and experience among researchers in a global context. Original papers, case reports, and invited reviews on all aspects of the kidney diseases, hypertension, dialysis, and transplantation will be covered by the IJKD. Research on the basic science, clinical practice, and socio-economics of renal health are all welcomed by the editors of the journal.